Albert Bourla, Pfizer CEO (Lintao Zhang/Getty Images)
May 2, 2023 09:58 AM EDTUpdated 01:24 PM
R&D
Pharma

Pfiz­er culls some Are­na-ac­quired pro­grams as it looks to­ward new launch­es

Kyle LaHucik

Senior Reporter

As Pfiz­er works to con­sum­mate a mega-merg­er with Seagen to prop up its on­col­o­gy pipeline and prod­uct port­fo­lio, the Big Phar­ma dis­closed some pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

Am­gen makes pipeline cuts, but obe­si­ty plans re­main the fo­cus

Ab­b­Vie adds to T cell en­gager mo­men­tum, with EvolveIm­mune pact start­ing at $65M

Q&A: Jade CEO talks about re­verse merg­er and IgAN drugs

A service from the Financial Times